Overview
Autosomal dominant coarctation of aorta refers to a familial form of coarctation of the aorta, a heart condition where a section of the aorta (the large blood vessel that carries blood from the heart to the rest of the body) is abnormally narrowed. This narrowing forces the heart to work harder to pump blood through the body, which can lead to high blood pressure in the arms and upper body, while blood pressure in the legs may be lower than normal. This particular entry in medical databases is now considered obsolete, meaning it has been reclassified or merged into broader categories of congenital heart defects with autosomal dominant inheritance patterns. The condition is present from birth, though it may not be detected until later in life depending on the severity of the narrowing. Symptoms can include high blood pressure, headaches, leg cramps or cold feet, nosebleeds, and in severe cases, heart failure. In newborns, severe coarctation can be life-threatening and may require emergency treatment. Treatment typically involves surgical repair or catheter-based procedures to widen the narrowed section of the aorta. With early diagnosis and appropriate treatment, many people with coarctation of the aorta can lead relatively normal lives, though lifelong follow-up with a cardiologist is important because the condition can recur or lead to other heart problems over time. The familial (autosomal dominant) form suggests that the condition runs in families and can be passed from parent to child with a 50% chance in each pregnancy.
Key symptoms:
High blood pressure in the armsLow blood pressure or weak pulses in the legsHeadachesNosebleedsCold feet or legsLeg cramps or pain during exerciseShortness of breathChest painDizziness or faintingDifficulty feeding in infantsPoor growth in babiesHeart murmurFatigue or tiredness with physical activity
Autosomal dominant
Passed on from just one parent; each child has about a 50% chance of inheriting it
Variable
Can begin at different ages, from infancy through adulthood
FDA & Trial Timeline
7 eventsUniversity Medical Centre Ljubljana
Shubo Song — NA
Boston Children's Hospital
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
No FDA-approved treatments are currently listed for OBSOLETE: Autosomal dominant coarctation of aorta.
6 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.
View clinical trials →Specialists
View all specialists →No specialists are currently listed for OBSOLETE: Autosomal dominant coarctation of aorta.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to OBSOLETE: Autosomal dominant coarctation of aorta.
Community
No community posts yet. Be the first to share your experience with OBSOLETE: Autosomal dominant coarctation of aorta.
Start the conversation →Latest news about OBSOLETE: Autosomal dominant coarctation of aorta
No recent news articles for OBSOLETE: Autosomal dominant coarctation of aorta.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is the coarctation, and does it need to be repaired now or can it be monitored?,What type of repair is recommended — surgery or catheter-based procedure — and what are the risks?,Should other family members be screened for coarctation or other heart defects?,What are the chances the narrowing could come back after repair?,Will my child (or I) need to take blood pressure medication long-term?,Are there any activity or exercise restrictions after treatment?,Should we pursue genetic testing to understand the familial pattern better?
Common questions about OBSOLETE: Autosomal dominant coarctation of aorta
What is OBSOLETE: Autosomal dominant coarctation of aorta?
Autosomal dominant coarctation of aorta refers to a familial form of coarctation of the aorta, a heart condition where a section of the aorta (the large blood vessel that carries blood from the heart to the rest of the body) is abnormally narrowed. This narrowing forces the heart to work harder to pump blood through the body, which can lead to high blood pressure in the arms and upper body, while blood pressure in the legs may be lower than normal. This particular entry in medical databases is now considered obsolete, meaning it has been reclassified or merged into broader categories of congen
How is OBSOLETE: Autosomal dominant coarctation of aorta inherited?
OBSOLETE: Autosomal dominant coarctation of aorta follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
Are there clinical trials for OBSOLETE: Autosomal dominant coarctation of aorta?
Yes — 6 recruiting clinical trials are currently listed for OBSOLETE: Autosomal dominant coarctation of aorta on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.